- Significantly Boosts EUSA’s Portfolio of Oncology and Rare Disease Products - Adds the Only FDA & EMA Approved Treatment for Idiopathic Multicentric Castleman’s Disease - Leverages EUSA’s Newly Expanded US Commercial Platform    Hemel Hempstead, ENGLAND and Boston, MA – 9 January 2019 EUSA Pharma (EUSA), a global biopharmaceutical company [...]
BOSTON and HEMEL HEMPSTED, England, December 5, 2018 EUSA Pharma (EUSA), a global biopharmaceutical company with a focus on oncology and rare disease, today announced the appointment of Jeffrey S. Hackman as President of its United States' operations. Mr Hackman will lead a major expansion of the company's US organization, as EUSA completes its tr[...]
- Acquisition significantly boosts EUSA Pharma’s presence as a global biopharmaceutical company in oncology and rare disease - SYLVANT® is the only FDA and EMA approved treatment for the rare disorder, idiopathic multicentric Castleman’s disease (iMCD) - Leverages EUSA Pharma’s commercial and medical expertise in rapidly advancing therapies to ad[...]
HEMEL HEMPSTEAD, England – 12 July 2018 – EUSA Pharma today welcomed a decision by the National Institute for Health and Care Excellence (NICE) to recommend the use of the targeted cancer immunotherapy, QARZIBA® (dinutuximab beta) to treat children with high-risk neuroblastoma within the NHS in England and Wales.[i] High-risk neuroblastoma is an ag[...]
Completes EUSA’s transition into oncology and rare disease-focused biopharmaceutical company – - Expands SERB’s product portfolio for rare and life-threatening diseases and supports the company’s expansion -   HEMEL HEMPSTEAD, England – 11th July 2018 – EUSA Pharma (EUSA) today announced it has entered into a definitive agreement with SERB Pharm[...]
FOTIVDA®▼ (tivozanib), shown to delay kidney cancer progression for almost a year, approved for use across Scotland   HEMEL HEMPSTEAD, England – 9 July 2018 – EUSA Pharma has welcomed advice from the Scottish Medicines Consortium (SMC) that approves the use of the once-daily oral capsule, FOTIVDA® (tivozanib), as a first-line treatment for people[...]
HEMEL HEMPSTEAD, England – 12 February 2018 – EUSA Pharma (EUSA), today announced that the National Institute for Health and Care Excellence (NICE) has published a Final Appraisal Determination (FAD) recommending tivozanib as a first-line treatment option for advanced renal cell carcinoma (aRCC) in line with its licensed indication. Tivozanib was l[...]
Oral Presentation Delivered at the 16th International Kidney Cancer Symposium CAMBRIDGE, Mass., USA and HEMEL HEMPSTEAD, England –– November 6, 2017 – AVEO Oncology (NASDAQ: AVEO) and EUSA Pharma today announced the presentation of promising results from the ongoing Phase 1 portion of the TiNivo study, a Phase 1/2 multicenter trial of tivozanib (F[...]
Exercise of Option Triggers $2.0 Million Research and Development Payment to AVEO CAMBRIDGE, Mass., USA and HEMEL HEMPSTEAD, England – September 20, 2017 – AVEO Oncology (NASDAQ: AVEO) and EUSA Pharma today announced that EUSA Pharma, under its multi-territory licensing agreement with AVEO for FOTIVDA® (tivozanib), has opted into the Phase 1/2 TiN[...]
HEMEL HEMPSTEAD, England – 28th August 2017 – EUSA Pharma (EUSA), today announced that the European Commission (EC) has licensed FOTIVDA® for the management of adult patients with advanced renal cell carcinoma (RCC) in the European Union plus Norway and Iceland. Tivozanib is indicated for the first line treatment of adult patients with advanced ren[...]
HEMEL HEMPSTEAD, England – 23 June 2017 – EUSA Pharma (EUSA), a specialty pharmaceutical company with a focus on oncology and oncology supportive care, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorisation of FOTIVDA (tivoz[...]
HEMEL HEMPSTEAD, England – 9th May 2017 – EUSA Pharma today announced that the European Commission (EC) has approved the antibody ch14.18/CHO, dinutuximab beta, for the treatment of high-risk neuroblastoma in patients aged 12 months and above.(1) Today's announcement makes dinutixumab beta the only approved immunotherapy in Europe for high risk neu[...]
HEMEL HEMPSTEAD, England and VIENNA, Austria – 27 March 2017 – EUSA Pharma (EUSA), a specialty pharmaceutical company with a focus on oncology and oncology supportive care, and Apeiron Biologics today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommendin[...]
HEMEL HEMPSTEAD, England and VIENNA, Austria – 4 October 2016 – EUSA Pharma (EUSA), a specialty pharmaceutical company with a focus on oncology and oncology supportive care, today announced the acquisition of exclusive global commercialization rights to the oncology product dinutuximab beta from Apeiron Biologics. Dinutuximab beta is currently used[...]
HEMEL HEMPSTEAD, England and HOKKSUND, Norway – 12 April 2016 – EUSA Pharma (EUSA), a recently-established specialty pharmaceutical company with a focus on oncology and oncology supportive care, today announced the acquisition of the global rights to a next generation formulation of EUSA’s current Caphosol® product from Arcoral Pharma AS. The produ[...]
HEMEL HEMPSTEAD, England and CAMBRIDGE, Mass. – March 1, 2016 – EUSA Pharma, a newly-established specialty pharmaceutical business, and AVEO Oncology (NASDAQ:AVEO) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency for tivozanib for the first-line treatment of advanced renal cell carcinoma[...]
CAMBRIDGE, Mass. and HEMEL HEMPSTEAD, England – December 21, 2015 – AVEO Oncology (NASDAQ:AVEO) and EUSA Pharma, a newly-established specialty pharmaceutical business with global reach, today announced an exclusive license agreement in which AVEO has granted EUSA Pharma European rights to tivozanib for the treatment of advanced renal cell carcinoma[...]
Hemel Hempstead, UK – 9 September 2015 – EUSA Pharma (EUSA), a recently-established specialty pharmaceutical company with global reach, today announced the appointment of William W Crouse to its Board of Directors. Mr Crouse brings to EUSA 50 years’ experience of the life sciences industry. In his most recent role he was a General Partner at Healt[...]
Hemel Hempstead, UK – 21 April 2015 – EUSA Pharma (EUSA), a recently-established profitable specialty pharmaceutical company with global reach, today announced the appointment of Lee Morley as Chief Executive Officer, and Dr Göran Ando as a Non-Executive Director. Bryan Morton, who established EUSA Pharma as founder and first CEO, will become Execu[...]
Hemel Hempstead, UK – 23 March 2015 – EUSA Pharma (EUSA), a newly-established profitable specialty pharmaceutical business with global reach, today announced its official launch following the acquisition of five approved specialty hospital products, a multi-national commercial infrastructure and the EUSA Pharma brand name from Jazz Pharmaceuticals [...]